Engaged in advancing innovative solutions for large-scale market applications
OMER, Israel, April 12, 2021 – Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced that Polyrizon Ltd. (which Medigus owns 33.24% of its share capital), a private company engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, commenced a pre-clinical trial to examine its bio-gel efficacy to protect against coronavirus infection.
Polyrizon develops an innovative technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities. Polyrizon’s technology is comprised of a bio-gel that is applied topically, and can be formulated both for wet and dry administration.
Polyrizon plans on testing a number of different formulations of its highly differentiae biological gel for protection against coronavirus, and on screening several new formulations designed to prevent coronavirus from effecting epithelial cells.
The trial results will provide guidance to Polyrizon for future regulatory process, as well as refine its existing formulations, and facilitate in the determination of which formulation is the most promising.
Medigus Ltd. is a technology-based company engaged in advancing innovative solutions for large-scale market applications. To learn more about Medigus’ advanced technology, please visit www.medigus.com.